^
Association details:
| Biomarker: | HK2 overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer
Excerpt:
...to predict the efficacy of cetuximab in metastatic colorectal cancer (mCRC) remains unclear....For progression-free survival (PFS) with first-line cetuximab plus chemotherapy, patients with high HK2 expression exhibited longer PFS compared with those with low HK2 expression (23.9 months vs. 6.9 months; P=0.021).
DOI:
10.3892/ol.2018.8005
